Advertisement






Click here for more guidelines.
CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 2006; 48:2186-2191, doi:10.1016/j.jacc.2005.12.084
© 2006 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (23)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gurbel, P. A.
Right arrow Articles by Tantry, U. S.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Gurbel, P. A.
Right arrow Articles by Tantry, U. S.

CLINICAL RESEARCH: INTERVENTIONAL CARDIOLOGY

Effect of Clopidogrel With and Without Eptifibatide on Tumor Necrosis Factor-Alpha and C-Reactive Protein Release After Elective Stenting

Results From the CLEAR PLATELETS 1b Study

Paul A. Gurbel, MD, FACC*, Kevin P. Bliden, BS and Udaya S. Tantry, PhD

Sinai Center for Thrombosis Research, Baltimore, Maryland.

Manuscript received October 20, 2005; revised manuscript received December 14, 2005, accepted December 19, 2005.

* Reprint requests and correspondence: Dr. Paul A. Gurbel, Sinai Center for Thrombosis Research, Hoffberger Building, Suite 56, 2401 W. Belvedere Avenue, Baltimore, Maryland 21215. (Email: pgurbel{at}lifebridgehealth.org).

OBJECTIVES: This study was performed to compare the effects of antiplatelet regimens on early inflammation and cardiac marker release after elective stenting.

BACKGROUND: Few data exist regarding the comparative effects of specific antiplatelet regimens on early inflammation marker release after stenting.

METHODS: In a 2 x 2 factorial randomized investigation, patients undergoing stenting were treated with either clopidogrel alone (300 mg or 600 mg; n = 60) or clopidogrel with eptifibatide (n = 60). Platelet aggregation (5 and 20 µM adenosine diphosphate [ADP]), ADP-stimulated expression of active glycoprotein (GP) IIb/IIIa, and platelet-bound P-selectin, tumor necrosis factor (TNF)-{alpha}, C-reactive protein (CRP), and cardiac markers were measured.

RESULTS: Compared with a strategy of clopidogrel alone, clopidogrel + eptifibatide reduced the release of cardiac markers. A marked reduction in platelet aggregation and active GP IIb/IIIa expression (p ≤ 0.001) with clopidogrel + eptifibatide was associated with a decrease in CRP and TNF-{alpha} release (p ≤ 0.001).

CONCLUSIONS: A strategy of clopidogrel with GP IIb/IIIa blockade resulted in superior inhibition of inflammation and cardiac marker release, which was accompanied by superior platelet inhibition immediately after percutaneous coronary intervention compared with a strategy of clopidogrel alone. The mechanistic and clinical implications of attenuated periprocedural inflammation and myocardial necrosis with a strategy of GP IIb/IIIa inhibition warrant further investigation.

Abbreviations and Acronyms
  ADP = adenosine diphosphate
  CK = creatinine kinase
  CLEAR PLATELETS = Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets
  CRP = C-reactive protein
  ELISA = enzyme-linked immunosorbent assay
  GP IIb/IIIa = glycoprotein IIb/IIIa
  MFI = mean fluorescence intensity
  PCI = percutaneous coronary intervention
  TNF = tumor necrosis factor




This article has been cited by other articles:


Home page
J Am Coll CardiolHome page
P. A. Gurbel, K. P. Bliden, J. F. Saucedo, T. A. Suarez, J. DiChiara, M. J. Antonino, E. Mahla, A. Singla, W. R. Herzog, A. K. Bassi, et al.
Bivalirudin and Clopidogrel With and Without Eptifibatide for Elective Stenting: Effects on Platelet Function, Thrombelastographic Indexes, and Their Relation to Periprocedural Infarction Results of the CLEAR PLATELETS-2 (Clopidogrel With Eptifibatide to Arrest the Reactivity of Platelets) Study.
J. Am. Coll. Cardiol., February 24, 2009; 53(8): 648 - 657.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
R Iijima, R A Byrne, G Ndrepepa, S Braun, J Mehilli, P B Berger, A Schomig, and A Kastrati
Pre-procedural C-reactive protein levels and clinical outcomes after percutaneous coronary interventions with and without abciximab: pooled analysis of four ISAR trials
Heart, January 15, 2009; 95(2): 107 - 112.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll Cardiol IntvHome page
D. J. Kereiakes and P. A. Gurbel
Peri-Procedural Platelet Function and Platelet Inhibition in Percutaneous Coronary Intervention
J. Am. Coll. Cardiol. Intv., April 1, 2008; 1(2): 111 - 121.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
P. A. Gurbel, R. C. Becker, K. G. Mann, S. R. Steinhubl, and A. D. Michelson
Platelet Function Monitoring in Patients With Coronary Artery Disease
J. Am. Coll. Cardiol., November 6, 2007; 50(19): 1822 - 1834.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
D. J. Angiolillo, A. Fernandez-Ortiz, E. Bernardo, F. Alfonso, C. Macaya, T. A. Bass, and M. A. Costa
Variability in Individual Responsiveness to Clopidogrel: Clinical Implications, Management, and Future Perspectives
J. Am. Coll. Cardiol., April 10, 2007; 49(14): 1505 - 1516.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
K. P. Bliden, J. DiChiara, U. S. Tantry, A. K. Bassi, S. K. Chaganti, and P. A. Gurbel
Increased Risk in Patients With High Platelet Aggregation Receiving Chronic Clopidogrel Therapy Undergoing Percutaneous Coronary Intervention: Is the Current Antiplatelet Therapy Adequate?
J. Am. Coll. Cardiol., February 13, 2007; 49(6): 657 - 666.
[Abstract] [Full Text] [PDF]



 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement